title: T-cell-directed therapies in systemic lupus erythematosus.
abstract: Drug development for the treatment of systemic lupus erythematosus (SLE) has largely focused on B-cell therapies. A greater understanding of the immunopathogenesis of SLE coupled with advanced bioengineering has allowed for clinical trials centered on other targets for SLE therapy. The authors discuss the benefits and shortcomings of focusing on T-cell-directed therapies in SLE and lupus nephritis clinical trials.
authors: Division of Rheumatology, Northwell Health, Great Neck, NY, USA pnandkumar@northwell.edu.
authors: P
authors: P
authors: Nandkumar
authors: Division of Rheumatology, Northwell Health, Great Neck, NY, USA.
authors: R
authors: R
authors: Furie
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D023201:CD40 Ligand / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000276:immunology* / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D023201:CD40 Ligand
keywords: Systemic lupus erythematosus; T-cell therapy; clinical trials; lupus nephritis; treatment